Can you answer this IB interview question?

Which is more important and why: revenue synergies, cost synergies, or a strategic acquisition?

Cost synergies are generally most important because they are highly quantifiable, within management's control, and realized quickly, though in IP- or pipeline-driven deals, strategic rationale can dominate the acquisition thesis.

Intuition

Cost synergies are most important because they are entirely within the acquirer's control — you can fire people and close offices on Day 1. Revenue synergies require customers to cooperate, which introduces uncertainty. Strategic rationales are the least reliable because they are often subjective justifications that can disguise value destruction.

Watch

A common follow-up is: 'If cost synergies are most important, why do acquirers frequently cite strategic rationale as the primary deal driver?' The answer is that strategic rationale drives the decision to pursue a deal, but cost synergies drive the ability to justify the price paid — these serve different purposes in the deal process.

Deep Dive

Determine which type of M&A benefit — revenue synergies, cost synergies, or strategic value — matters most, and explain the reasoning in terms of how each is quantified and realized.

Core Ranking: Cost Synergies > Revenue Synergies > Strategic Rationale (in terms of reliability and bankability)

But the real answer is: it depends on the deal, and interviewers want you to explain why the hierarchy exists.

Step 1: Why Cost Synergies Are Most Credible

They are within management's direct control: headcount reductions, facility consolidations, duplicate vendor contracts, overlapping IT systems.

They are quantifiable pre-close with high precision. You can literally count redundant roles.

Realization timeline is short: typically 75–100% captured within 1–2 years.

Buyers and their boards will assign near-full credit to cost synergies in valuation models.

Present value impact: if annual cost synergies = $S_{c}$ , the capitalized value at the buyer's WACC is approximately

\text{PV}_{\text{cost}} = \frac{S_c \times (1 - t)}{\text{WACC}} $$ which flows straight to the combined entity's bottom line with high certainty. **Step 2: Why Revenue Synergies Are Less Reliable** - They depend on customer behavior, competitive response, and execution across two merging sales organizations — none of which management fully controls. - Cross-selling, geographic expansion, and pricing power are plausible but hard to guarantee. - Realization rates are historically low: studies suggest only 25–50% of projected revenue synergies are actually captured. - Timeline is longer: 3–5 years to materialize. - Because of this uncertainty, acquirers and their advisors typically discount or haircut revenue synergies heavily (often 50%+) in accretion/dilution and purchase-price justification analyses. - Capitalized value:

\text{PV}_{\text{revenue}} = \frac{\Delta R \times \text{Incremental Margin} \times (1 - t)}{\text{WACC}} $$ but you must apply a probability weight to $Δ R$ reflecting execution risk.

Step 3: Why Strategic Rationale Ranks Last in Quantifiable Terms

Strategic benefits (entering new markets, acquiring talent/IP, defensive positioning against competitors) are real but nearly impossible to model with precision.

They often serve as qualitative justification for a premium that cost and revenue synergies alone cannot support.

Danger zone: when a deal is justified primarily on strategic grounds with no quantifiable synergy backing, it is most likely to destroy value (empirically, most "strategic" deals that overpay do).

Comparison Table:

Dimension	Cost Synergies	Revenue Synergies	Strategic Rationale
Controllability	High	Medium	Low
Quantifiability	High	Moderate	Low / Qualitative
Typical realization	75–100%	25–50%	Difficult to measure
Time to capture	1–2 years	3–5 years	Uncertain
Credit given in models	~100%	~50% (haircut)	Often $0 in base case
Risk of overpaying	Low	Moderate	High

Step 4: The Nuanced Answer Interviewers Want

State the hierarchy: cost > revenue > strategic in terms of reliability.

Then note the exception: in certain deals (e.g., tech/pharma acquisitions for IP or pipeline), the strategic value IS the entire thesis, and cost/revenue synergies are secondary. In those cases, the buyer is paying for optionality on future cash flows that don't yet exist.

The key principle: the more controllable and quantifiable the benefit, the more weight it deserves in justifying the acquisition premium.